Vitality Watch

Dossier clinicaltrials trial early 11-jun-2026
Small or early-phase human trial or pilot study

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Key claim: A planned double-blind RCT will test whether creatine monohydrate plus 12-week supervised resistance training improves muscle mass, strength, density, and physical function (sarcopenia parameters) in men with prostate cancer on androgen deprivation therapy.

Abstract

This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical performance (e.g., parameters of sarcopenia), and muscle density in men with prostate cancer undergoing androgen deprivation therapy (ADT). ADT often causes loss of lean mass, reduced muscle strength, functional impairment, and increased fat mass. Eligible male patients will be randomly assigned to receive either creatine monohydrate or a placebo (maltodextrin) in a double-blind manner, in addition to participating in the resistance exercise program. Assessments will be performed at baseline and after the 12-week intervention period and will include:

  • Muscle density and architecture assessed by ultrasound
  • Body composition (lean mass and fat mass)
  • Muscle strength
  • Physical performance (functional performance tests)
  • Inflammatory biomarkers
  • Vascular function parameters

The primary goal is to assess whether creatine supplementation combined with resistance training can safely improve muscle quality and quantity, strength, and physical function in these patients. If effective and safe, the intervention could help reduce muscle loss and improve quality of life in men undergoing ADT.

Why this matters

Androgen deprivation therapy reliably accelerates sarcopenia, making ADT-treated prostate cancer patients a high-signal population for testing whether creatine — the best-evidenced ergogenic adjunct to resistance training in healthy older adults — carries over to a hypogonadal clinical setting. As a protocol registration, it adds a planned readout rather than new efficacy data, but marks where the RT+creatine literature is expanding from general aging into oncology-driven muscle loss.

Source

Link

Briefing card

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy
Stage: trial early · clinicaltrials · 11-jun-2026

A planned double-blind RCT will test whether creatine monohydrate plus 12-week supervised resistance training improves muscle mass, strength, density, and physical function (sarcopenia parameters) in men with prostate cancer on androgen deprivation therapy.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07463092

build build 880 · 2bcef25 · 2026-11-18